This is a schematic of the selective isolation of a patient's own tumor-reactive T cells. Credit: Daniel Powell, PhD, Perelman School of Medicine, University of Pennsylvania
Patients with tumors that contain increased numbers of T lymphocytes generally survive longer than those with tumors without T-cell involvement, suggesting that T cells with potent antitumor function naturally exist in cancer and control tumor progression. With the exception of melanoma, it has been difficult to identify and isolate the tumor-reactive T cells from common cancers, however, the ability to do so could be used to fight a patient's own cancer.
In a paper recently published in Clinical Cancer Research, investigators in the lab of Daniel Powell, PhD, at the Perelman School of Medicine, University of Pennsylvania, demonstrated for the first time that a T cell activation molecule can be used as a biomarker to identify rare antitumor T cells in human cancers. The molecule, CD137, is a protein that is not normally found on the surface of resting T cells but its expression is induced when the T cell is activated.
In their work, Powell and colleagues developed a rapid system to accurately isolate these cells directly from human tumor tissue. TILs, short for tumor-infiltrating lymphocytes – are white blood cells that have left the bloodstream and migrated into tumor tissue. They took human tumor samples that contained TILs, disrupted them to single cell suspensions, and cultured the mix of tumor cells and TILs overnight. The next morning they selectively captured the TILs that expressed the CD137 molecule.
In a test tube-based experiment, the team showed that the isolated CD137 T cells recognize cancers cells taken from the same patient. The T cells recognize proteins (called antigens, immunologically) presented by the tumor cells as small peptides derived from inside the cell.
After isolating the CD137 cells from other non-reactive TILs and tumor cells, they theoretically could be given back to the patient as a concentrated dose of their own tumor-fighting cells. To model this, the team injected cancer cells in combination with the CD137 TILs into immune-deficient mice. The CD137 TILs actively controlled tumor progression, while TILs that did not express CD137 from the same patient had no impact on tumor growth.
Giving large numbers of patients' tumor-reactive T cells back to the same patient can lead to cancer eradication in melanoma, but investigators have had a hard time doing the same for other cancers. However, Powell and colleagues showed that their new approach can be used in a variety of cancers, including melanoma and ovarian cancer, which suggests this promising therapy can now be widely applied.
This field has a growing enthusiasm for T-cell therapy, says Powell. The initial findings are encouraging and have produced additional questions to be answered: How do CD137 cells control tumor growth? In what other cancers do similar tumor-reactive T cells exist? How can we identify, expand, and use them? How can we use this new knowledge to shorten the time to make TILs for clinical trials? Powell and colleagues are working diligently to address these questions and move the current approach forward.
Explore further: New screening approach identifies small proteins unique to melanoma cells, researcher says
More information: clincancerres.aacrjournals.org/content/early/2013/09/17/1078-0432.CCR-13-0945.full.pdf+html
Medical Xpress on facebook
Related Stories
New screening approach identifies small proteins unique to melanoma cells, researcher says
Jun 25, 2013
Jamie K. Teer, Ph.D., assistant member of the Cancer Biology and Evolution Program at Moffitt Cancer Center, and colleagues have developed a new streamlined method to rapidly identify the genetic changes in small protein ...
Enhancing the effectiveness of a breast cancer treatment
Feb 13, 2012
Breast cancers expressing the protein HER2 have a particularly poor prognosis. Treatment with trastuzumab (Herceptin) benefits some patients with HER2-positive breast cancer, but it is not as effective as had been hoped. ...
Engineered T cells kill tumors but spare normal tissue in an animal model
Apr 07, 2013
The need to distinguish between normal cells and tumor cells is a feature that has been long sought for most types of cancer drugs. Tumor antigens, unique proteins on the surface of a tumor, are potential targets for a normal ...
Zebrafish shown to be useful tool in prostate cancer stem cell research
Nov 07, 2013
(Medical Xpress)—Research from Rutgers Cancer Institute of New Jersey demonstrates that using zebrafish to identify self-renewing tumor stem cells in prostate cancers may be more beneficial than using traditional experimental ...
Enhanced luminal breast tumor response to antiestrogen therapy
Sep 03, 2013
Breast cancer can be divided into 4 major subtypes using molecular and genetic information from the tumors. Each subtype is associated with different prognosis and should be taken into consideration when making treatment ...
Recommended for you
Personalized medicine: New biomarker for oral cancer
4 hours ago
(Medical Xpress)—University of Toronto researchers have identified a protein that can help doctors predict whether a patient will develop oral cancer – one of the most common cancers in Asia.
Study finds new explanation for resistance to breast cancer treatment
5 hours ago
Breast cancers that initially respond to hormone therapies such as tamoxifen eventually become resistant to treatment, and a new study finds this may be because of a mutation in the receptor present in the cancer cell to ...
Clinical trial finds concurrent therapy not necessary to achieve high pathological in breast cancer
9 hours ago
Giving trastuzumab and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity. New research ...
Epigenetic silencing of the HAND2 tumor suppressor promotes endometrial cancer
19 hours ago
A study published this week in PLOS Medicine suggests that epigenetic modification of the HAND2 gene plays a critical role in the development of endometrial cancer. HAND2 is active in the healthy endometrium (the tissue lining ...
Researchers find a new solution in detecting breast-cancer related lymphedem
21 hours ago
Viewed as one of the most feared outcomes of breast cancer treatment, doctors struggle detecting and diagnosing breast-cancer related Lymphedema—a condition affecting the lymphatic system and causing psychosocial ...
Controlling the hormonal environment in endometrial cancer sensitizes tumors to PARP inhibitors
23 hours ago
Modulating the hormonal environment in which endometrial cancers grow could make tumors significantly more sensitive to a new class of drugs known as PARP inhibitors, UCLA researchers have shown for the first time.
User comments
© Medical Xpress 2011-2013, Phys.org network
This is a schematic of the selective isolation of a patient's own tumor-reactive T cells. Credit: Daniel Powell, PhD, Perelman School of Medicine, University of Pennsylvania
Patients with tumors that contain increased numbers of T lymphocytes generally survive longer than those with tumors without T-cell involvement, suggesting that T cells with potent antitumor function naturally exist in cancer and control tumor progression. With the exception of melanoma, it has been difficult to identify and isolate the tumor-reactive T cells from common cancers, however, the ability to do so could be used to fight a patient's own cancer.
In a paper recently published in Clinical Cancer Research, investigators in the lab of Daniel Powell, PhD, at the Perelman School of Medicine, University of Pennsylvania, demonstrated for the first time that a T cell activation molecule can be used as a biomarker to identify rare antitumor T cells in human cancers. The molecule, CD137, is a protein that is not normally found on the surface of resting T cells but its expression is induced when the T cell is activated.
In their work, Powell and colleagues developed a rapid system to accurately isolate these cells directly from human tumor tissue. TILs, short for tumor-infiltrating lymphocytes – are white blood cells that have left the bloodstream and migrated into tumor tissue. They took human tumor samples that contained TILs, disrupted them to single cell suspensions, and cultured the mix of tumor cells and TILs overnight. The next morning they selectively captured the TILs that expressed the CD137 molecule.
In a test tube-based experiment, the team showed that the isolated CD137 T cells recognize cancers cells taken from the same patient. The T cells recognize proteins (called antigens, immunologically) presented by the tumor cells as small peptides derived from inside the cell.
After isolating the CD137 cells from other non-reactive TILs and tumor cells, they theoretically could be given back to the patient as a concentrated dose of their own tumor-fighting cells. To model this, the team injected cancer cells in combination with the CD137 TILs into immune-deficient mice. The CD137 TILs actively controlled tumor progression, while TILs that did not express CD137 from the same patient had no impact on tumor growth.
Giving large numbers of patients' tumor-reactive T cells back to the same patient can lead to cancer eradication in melanoma, but investigators have had a hard time doing the same for other cancers. However, Powell and colleagues showed that their new approach can be used in a variety of cancers, including melanoma and ovarian cancer, which suggests this promising therapy can now be widely applied.
This field has a growing enthusiasm for T-cell therapy, says Powell. The initial findings are encouraging and have produced additional questions to be answered: How do CD137 cells control tumor growth? In what other cancers do similar tumor-reactive T cells exist? How can we identify, expand, and use them? How can we use this new knowledge to shorten the time to make TILs for clinical trials? Powell and colleagues are working diligently to address these questions and move the current approach forward.
Explore further: New screening approach identifies small proteins unique to melanoma cells, researcher says
More information: clincancerres.aacrjournals.org/content/early/2013/09/17/1078-0432.CCR-13-0945.full.pdf+html
Medical Xpress on facebook
Related Stories
New screening approach identifies small proteins unique to melanoma cells, researcher says
Jun 25, 2013
Jamie K. Teer, Ph.D., assistant member of the Cancer Biology and Evolution Program at Moffitt Cancer Center, and colleagues have developed a new streamlined method to rapidly identify the genetic changes in small protein ...
Enhancing the effectiveness of a breast cancer treatment
Feb 13, 2012
Breast cancers expressing the protein HER2 have a particularly poor prognosis. Treatment with trastuzumab (Herceptin) benefits some patients with HER2-positive breast cancer, but it is not as effective as had been hoped. ...
Engineered T cells kill tumors but spare normal tissue in an animal model
Apr 07, 2013
The need to distinguish between normal cells and tumor cells is a feature that has been long sought for most types of cancer drugs. Tumor antigens, unique proteins on the surface of a tumor, are potential targets for a normal ...
Zebrafish shown to be useful tool in prostate cancer stem cell research
Nov 07, 2013
(Medical Xpress)—Research from Rutgers Cancer Institute of New Jersey demonstrates that using zebrafish to identify self-renewing tumor stem cells in prostate cancers may be more beneficial than using traditional experimental ...
Enhanced luminal breast tumor response to antiestrogen therapy
Sep 03, 2013
Breast cancer can be divided into 4 major subtypes using molecular and genetic information from the tumors. Each subtype is associated with different prognosis and should be taken into consideration when making treatment ...
Recommended for you
Personalized medicine: New biomarker for oral cancer
4 hours ago
(Medical Xpress)—University of Toronto researchers have identified a protein that can help doctors predict whether a patient will develop oral cancer – one of the most common cancers in Asia.
Study finds new explanation for resistance to breast cancer treatment
5 hours ago
Breast cancers that initially respond to hormone therapies such as tamoxifen eventually become resistant to treatment, and a new study finds this may be because of a mutation in the receptor present in the cancer cell to ...
Clinical trial finds concurrent therapy not necessary to achieve high pathological in breast cancer
9 hours ago
Giving trastuzumab and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity. New research ...
Epigenetic silencing of the HAND2 tumor suppressor promotes endometrial cancer
19 hours ago
A study published this week in PLOS Medicine suggests that epigenetic modification of the HAND2 gene plays a critical role in the development of endometrial cancer. HAND2 is active in the healthy endometrium (the tissue lining ...
Researchers find a new solution in detecting breast-cancer related lymphedem
21 hours ago
Viewed as one of the most feared outcomes of breast cancer treatment, doctors struggle detecting and diagnosing breast-cancer related Lymphedema—a condition affecting the lymphatic system and causing psychosocial ...
Controlling the hormonal environment in endometrial cancer sensitizes tumors to PARP inhibitors
23 hours ago
Modulating the hormonal environment in which endometrial cancers grow could make tumors significantly more sensitive to a new class of drugs known as PARP inhibitors, UCLA researchers have shown for the first time.
User comments
© Medical Xpress 2011-2013, Phys.org network
No comments:
Post a Comment